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Abstract
Patients with liver disease frequently have substantial changes in their haemostatic system. This is
reflected in abnormal test results on routine coagulation screening assays such as the prothrombin time
(PT), activated thromboplastin time (APTT) and platelet count. Traditionally, attempts were made to
correct abnormalities in the haemostatic system as measured by routine coagulation assays prior to
invasive procedures by infusion of platelets or fresh frozen plasma (FFP). Recent laboratory and clinical
data have indicated that the haemostatic reserve in cirrhotic patients is relatively well maintained although
the coagulation screening assays suggest otherwise. Pre-procedural correction of coagulation tests with
blood products may therefore not be necessary, and may even have harmful side-effects. In particular,
fluid overload resulting in exacerbation of portal hypertension by infusion of blood products may in fact
promote bleeding. In recent years, it has become clear that reduction of the central and portal venous
pressure by fluid restriction and avoidance of blood product transfusion is a beneficial strategy in
minimizing bleeding during liver surgery in cirrhotic patients. Some investigators have even taken this a
step further and suggested pre-procedural phlebotomy in liver transplant recipients. The aim of this
review is to provide an overview of recent studies and developments which have changed our under-
standing of the clinical relevance of abnormal coagulation tests in patients with cirrhosis, and which have
contributed to a reduction in blood loss and transfusion requirements when liver surgery is needed in
these patients.
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Introduction
Extensive blood loss is still a major concern in major surgical
procedures involving the liver, especially during partial liver resec-
tion and orthotopic liver transplantation (OLT). Although blood
loss in patients undergoing liver surgery has decreased substan-
tially during the last decade, (excessive) blood loss and transfusion
requirements are still a concern. Peri-operative blood loss and
transfusion of blood products are associated with increased rates
of morbidity and mortality, both in non-cirrhotic and cirrhotic
patients.1–4 Main causes of blood loss are thought to consist of
surgical and patient-related factors and impaired haemostasis. In
general, surgical factors may contribute to 75–90% of intra-
operative and early post-operative bleeding.5 In liver transplant
surgery, additional factors related to peri-operative blood loss are
severity of liver disease, concomitant renal failure, length of the
cold ischaemia time and the type of surgical technique used (non-
cava sparing versus cava sparing or piggy back technique).6,7 Addi-
tionally, in patients with a poor liver function, abnormalities in
the haemostatic system are thought to contribute significantly to
peri-operative bleeding. Nevertheless, a substantial proportion of
cirrhotic patients with poor haemostatic function can nowadays
undergo major invasive procedures, such as liver transplantation,
without the requirement for any blood transfusion.1,3,8 This may
imply that haemostatic alterations are not as clinically relevant in
determining peri-operative bleeding in cirrhotic patients as pre-
viously assumed. Support for a minor role of dysbalanced coagu-
lation in peri-operative blood loss has emerged from laboratory
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studies which have indicated that defects in pro-haemostatic path-
ways in patients with liver disease are compensated for, at least in
part, by concomitant deficiencies in anti-haemostatic systems.9–12
As routine tests of coagulation such as the prothrombin time (PT)
are only sensitive for procoagulant systems, prolonged PT values
in cirrhotics are often misinterpreted as representing a bleeding
tendency.13,14 Indeed, routine coagulation tests such as the PT are
poor predictors of blood loss during liver transplantation.15–17
Traditionally, attempts were made to reverse abnormal coagu-
lation tests in the cirrhotic patient prior to a surgical procedure by
the administration of blood products such as fresh frozen plasma
(FFP). However, it is debatable whether correction of abnormal
test results is really necessary, as these tests do not necessarily
reflect in vivo haemostasis.11,18 Moreover, transfusion of blood
products is associated with substantial side-effects, including fluid
overload. In recent years, it has become clear that maintenance of
a low central venous pressure (CVP) and even reduction of CVP
by phlebotomy is a beneficial strategy in minimizing blood loss
during liver resection or liver transplantation.8,19 Maintenance of a
low CVP requires a restrictive use of fluids and avoidance of
transfusion of (large volume) blood products, which implicates
that routine correction of abnormal coagulation tests may not be
essential to minimize intra-operative blood loss during surgical
liver surgery.
This paper provides an evaluation of clinical and laboratory
data used to guide peri-operative strategies directed at a reduction
in blood loss in cirrhotic patients undergoing surgery of the liver.
In particular, we will provide arguments that contraction of
volume is a better treatment to minimize bleeding during invasive
liver procedures than a routine correction of abnormal coagula-
tion tests by transfusion of (large volume) blood products.
Traditional concepts in the treatment of
altered haemostasis prior to liver surgery
Patients with end-stage liver disease suffer from complex haemo-
static disturbances, as a result of a reduction in platelet count and
platelet function, and a reduction in circulating levels of proteins
involved in coagulation and fibrinolysis.20 For years it was gener-
ally believed that there is a strong causal relation between abnor-
malities in the haemostatic system and the bleeding tendency in
patients with cirrhosis. These haemostatic differences result in
abnormalities in the routine screening tests of coagulation, such as
the PT, activated partial thromboplastin time (APTT) and the
bleeding time.
Traditionally, attempts were made to reverse the abnormalities
of routine haemostatic tests before initiation of liver surgery. In
particular, a prolonged PT was treated with infusion of FFP, and a
low platelet count was treated with platelet concentrates. This
policy, however, may not be effective and has a number of disad-
vantages. First of all, it has been shown in several studies that
abnormal pre-operative coagulation tests are a very poor predic-
tor of intra-operative bleeding.14–17 Second, correction of a pro-
longed PT with FFP does not result in complete normalization,
and the duration of the reversal is relatively short.21 Third, correc-
tion of a prolonged pre-operative PT by administration of re-
combinant factor (F)VIIa, does not result in a reduction of
intra-operative bleeding or transfusion requirements in cirrhotic
patients undergoing partial liver resection or transplantation.22–24
Although recombinant FVIIa is a very effective drug in normaliz-
ing a prolonged PT in patients with cirrhosis,25 several random-
ized controlled studies have shown that this does not result in a
subsequent reduction of intra-operative bleeding or transfusion
requirements, as compared with placebo.22–24 The only category of
pharmacological agents that has shown to be effective in reducing
blood loss during liver surgery in patients with cirrhosis is that
of antifibrinolytic drugs.26 Hyperfibrinolysis, however, is not
reflected by routine coagulation tests and cannot be corrected by
infusion of blood products.
Transfusion of large amounts of FFP may in fact be counter-
productive as it leads to fluid overload and a subsequent increase
of the central and portal venous pressure, which is already
elevated in many cirrhotic patients. The increase in portal pres-
sure may result in increased bleeding during abdominal surgical
dissection. Moreover, transfusion of blood products is associated
with important side-effects. It is well known that infusion of
platelets or FFP in general is associated with an increased risk of
infectious complications and respiratory complications, such as
pulmonary oedema and transfusion-related acute lung injury
(TRALI).27,28 These side-effects may account for the negative rela-
tion between intra-operative blood transfusion requirements and
post-operative infection rate, morbidity and mortality.2–4,29 Also in
liver transplant patients, platelet transfusions have been associated
with increased post-operative mortality, as a result of an increased
risk of acute lung injury.30
Altogether, these lines of evidence indicate that correction of a
prolonged PT in patients with cirrhosis does not necessarily trans-
late to improved haemostasis or reduced intra-operative blood
loss when these patients require liver surgery.
New insights in haemostatic function in
cirrhotic patients: a rebalance of the
haemostatic system?
Recent data from both laboratory models and clinical studies have
suggested that the haemostatic dysbalance in cirrhotic patients
may not be as severe as suggested by the routine coagulation tests.
Although commonly used tests such as the PT, APTT and the
bleeding time are frequently prolonged in patients with liver
failure, these tests may not reflect in vivo haemostasis in these
patients. Recent studies suggest that the haemostatic abnormali-
ties in patients with liver disease are compensated for, or ‘rebal-
anced’, as a result of concomitant alterations in both pro- and
anti-haemostatic systems (reviewed in 20). The defects in haemo-
static pathways that promote bleeding are balanced (in part) by
changes in the haemostatic system that actually promotes clot
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formation (see Table 1). For example, deficiencies in procoagulant
proteins may be balanced by deficiencies in anticoagulant pro-
teins. Tripodi and coworkers have shown that in patients with liver
disease and a prolonged PT, thrombin generation is indistinguish-
able from that of healthy volunteers, provided that the thrombin
generation test was executed in the presence of an activator of
the anticoagulant protein C system.11 This observation exempli-
fied that a prolonged PT does not necessarily translate into defec-
tive thrombin generation, as PT is only sensitive for levels of
procoagulant proteins. In the more sophisticated test as used by
Tripodi et al., the balance between pro- and anticoagulant pro-
teins is tested more accurately.
Similarly, it was shown that the fibrinolytic system may also be
rebalanced in patients with cirrhosis9 although these findings have
been challenged.31 Finally, the low platelet count in patients with
liver disease may be compensated for by highly elevated levels of
von Willebrand factor (VWF).10
Altogether, laboratory evidence suggests that the patient’s cir-
rhosis has a compensated or ‘rebalanced’ haemostatic system. It
has been suggested that this system may function adequately (no
bleeding or thrombosis), albeit with more narrow margins, com-
pared with healthy individuals.32 The more narrow margins may
explain why clinically overt bleeding complications may occur in
these patients when the haemostatic balance is heavily challenged
i.e. during episodes of sepsis. Conversely, thrombotic complica-
tions such as portal vein thrombosis, deep venous thrombosis and
pulmonary embolism may occur in patients with liver disease,33–37
despite the commonly accepted notion that these patients are
‘auto-anticoagulated’, as suggested by their prolonged coagulation
tests.
All these changing insights of the performance of the haemo-
static system in patients with cirrhosis have consequences for the
interpretation of pre-operative coagulation assays and for the pre-
and intra-operative management of cirrhotic patients undergoing
surgical procedures. This is supported by clinical data showing a
lack of excessive blood loss in many patients with end-stage liver
disease during liver transplantation, when abnormal coagulation
tests are not routinely corrected with the infusion of blood prod-
ucts, and the subtle haemostatic balance is left untouched as much
as possible by a restrictive infusion policy.1,8 A substantial propor-
tion of patients can nowadays be transplanted without the
requirement for any blood transfusion, and we believe that major
surgery without the requirement for transfusion would never be
possible in a patient with a true coagulopathy. Bleeding episodes
that do occur in patients with liver disease are often unrelated to
deranged coagulation, and appear to be a consequence of portal
hypertension and venous collaterals rather than coagulopathy (i.e.
variceal bleeding).
Volume contraction: an attractive strategy to
reduce blood loss during surgery in patients
with cirrhosis?
In view of the rebalanced haemostatic system, correction of hae-
mostatic abnormalities prior to surgical interventions by, for
example, plasma transfusion is not necessary and may even
be harmful. As discussed above, overfilling patients with blood
products is associated with an increased risk of morbidity and
mortality.
Bleeding complications in patients with liver disease may not
primarily be related to impaired coagulation. Alterations in hae-
modynamics and vessel wall function may play a more important
role in the bleeding tendency of cirrhotic patients. In particular,
the hyperdynamic circulation and the presence of portal hyper-
tension may be important factors in peri-operative bleeding in
these patients. Also in the non-surgical patient, the most common
bleeding complication, i.e. variceal bleeding, is as a result of vas-
cular abnormalities and increased portal venous pressure.38
Reduction of the systemic and portal venous pressure may be
therefore an attractive strategy for reduction of blood loss during
liver surgery. Indeed, the application of low CVP during liver
surgery has widely been studied.8,39–42 Low CVP is usually obtained
by fluid restriction, forced diuresis, venous vasodilatation or even
phlebotomy. Maintenance of a low CVP during partial resection
of non-cirrhotic livers is associated with a significant reduction in
blood loss.40–42 However, a low CVP may have serious side-effects
including renal failure, but reports on this have been contradic-
tory. Schroeder et al. compared two centres performing liver
transplantations.43 One liver transplantation centre adhered to a
low CVP policy (<5 mmHg) using fluid restriction, whereas the
second centre used a normal CVP (7 to 10 mmHg). Both patient
groups were similar in demographics, aetiology of liver disease
and surgical technique. Patients in the low CVP group received
significantly lower amounts of red blood cells, FFP and platelets
compared with patients in the normal CVP group. However, peak
Table 1 Alterations to the haemostatic system in patients with liver
disease that contribute to bleeding (left) or counteract bleeding
(right)
Changes that impair
haemostasis
Changes that promote
haemostasis
Thrombocytopenia Elevated levels of von Willebrand
factor
Platelet function defects Decreased levels of ADAMTS-13
Enhanced production of nitric
oxide and prostacyclin
Elevated levels of factor VIII
Low levels of factors II, V, VII, IX,
X, and XI
Decreased levels of protein C,
protein S, antithrombin,
a2-macroglobulin, and heparin
cofactor II
Vitamin K deficiency Low levels of plasminogen
Dysfibrinogenemia
Low levels of a2-antiplasmin,
factor XIII, and TAFI
Elevated t-PA levels
Source: Modified from the European Association for the Study of the
Liver from Lisman et al.20 with permission.
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serum creatinine (3.2 vs. 1.8 mg/dl, P < 0.01) and the need for
dialysis (6.8% vs. 1.2%, P < 0.05) were significantly higher in
patients with a low CVP during transplantation. In contrast, Wang
et al. found no significant differences in post-operative renal func-
tion when comparing two groups of 25 cirrhotic patients with a
low CVP (<4 mmHg) or normal CVP while undergoing partial
liver resection for hepatocellular carcinoma.44
Some investigators have taken the concept of avoiding fluid
overload and reducing central and portal venous pressure as
maximal as possible to a more extreme strategy and have even
proposed pre-operative phlebotomy in patients undergoing liver
transplantation.8,17 Using a combined strategy of fluid restriction
and pre-operative phlebotomy in patients undergoing liver trans-
plantation, Massicotte et al. have reported significant reduction in
intra-operative blood loss and transfusion requirements, when
compared with historical control patients with a more conven-
tional fluid management.8,17 The median red blood cell transfu-
sion requirement was 0.3 units and 81% of the patients did not
require any blood transfusion when applying this strategy.
Although such a strategy could be potentially associated with an
increased rate of other peri-operative complications, such as renal
failure or cardiac ischaemic events, these investigators did not
observe an increased need for post-operative renal replacement
therapy in a consecutive series of 200 patients.17
In Groningen, we have also adopted a fluid restriction policy in
patients undergoing partial liver resection or liver transplantation,
although we do not use extreme measures such as pre-operative
phlebotomy. Our policy is not to correct routinely abnormal pre-
operative coagulation tests with platelet or plasma transfusion.
Furthermore, we accept a haematocrit of 25–30%, maintain a low
CVP (<5 mmHg) and are very restrictive in transfusing FFP and
platelets peri-operatively.1,29 When indicated, we would rather use
vasopressors and diuretics to maintain adequate perfusion pres-
sure and diuresis than the additional infusion of fluids. Adoption
of a fluid restriction policy in our centre has been accompanied by
a steady decline in transfusion requirements, and a steady increase
in patients who are transplanted without the requirement for any
red blood cell (RBC) transfusion. During the past 5 years, around
40% of the adult patients undergoing a first liver transplant did
not require a RBC transfusion.1 Although we have not formally
studied whether the reduced transfusion requirements are as a
consequence of adoption of a very restrictive transfusion policy,
this has generally been the perception within the group of sur-
geons and anaesthetists. Several other centres have observed a
steady decline in FFP and RBC usage over the years, despite the
fact that the mean model for end-stage liver disease (MELD) score
of patients transplanted steadily increases over time.45
Conclusion
Recent data from laboratory models and clinic studies have dem-
onstrated that the coagulation system in cirrhotic patients is not
as abnormal as traditionally assumed, but is ‘rebalanced’ by con-
comitant deficiencies in pro- and anti-coagulant systems. These
changing insights in the performance of the haemostatic system
in patients with cirrhosis have consequences for the interpreta-
tion of pre-operative coagulation tests. Pre-operative coagulation
assays do not appear to predict bleeding in cirrhotic patients and
pre-procedural correction of abnormal coagulation assays with
blood or plasma products may therefore not be as effective as
traditionally assumed. In fact, efficacy of pre-procedural correc-
tion of haemostasis by administration of blood products in
patients with liver disease has never been demonstrated in appro-
priately designed clinical studies. Conversely, transfusion of
blood and plasma products has been associated with important
side-effects and may even increase the bleeding tendency by
inducing volume overload. Alterations in haemodynamics (i.e.
portal venous hypertension) and vessel wall function may play a
more important role in the bleeding tendency of patients with
end-stage liver disease than coagulation disturbances. Indeed,
strategies aiming at a reduction of central and portal venous
blood pressure by fluid restriction and avoidance of routine
transfusion of blood products have been associated with a reduc-
tion in peri-operative blood loss in cirrhotic patients undergoing
surgery of the liver.
Volume contraction and a very restrictive blood product trans-
fusion protocol may be more effective in reducing bleeding during
major surgical procedures involving the liver than routine correc-
tion of abnormal coagulation test (i.e. with large volumes of FFP).
Further clinical research should assess possible side-effects of
maintaining a low central pressure in cirrhotic patients. Moreover,
randomized controlled trials comparing different transfusion and
infusion protocols are urgently needed.
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